Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 1
2010 1
2014 1
2015 3
2016 9
2017 11
2018 3
2019 12
2020 16
2021 19
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Results by year
Filters applied: . Clear all
Page 1
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Sallman DA, et al. J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15. J Clin Oncol. 2021. PMID: 33449813 Clinical Trial.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. Malcovati L, et al. Among authors: sallman da. Blood. 2020 Jul 9;136(2):157-170. doi: 10.1182/blood.2020004850. Blood. 2020. PMID: 32347921 Free PMC article. Review.
Current status and new treatment approaches in TP53 mutated AML.
Hunter AM, Sallman DA. Hunter AM, et al. Among authors: sallman da. Best Pract Res Clin Haematol. 2019 Jun;32(2):134-144. doi: 10.1016/j.beha.2019.05.004. Epub 2019 May 11. Best Pract Res Clin Haematol. 2019. PMID: 31203995 Review.
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.
Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, Sallman DA, Komrokji RS, Goldberg AD. Ball BJ, et al. Among authors: sallman da. Blood Adv. 2020 Jul 14;4(13):2866-2870. doi: 10.1182/bloodadvances.2020001482. Blood Adv. 2020. PMID: 32589727 Free PMC article.
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al Ali NH, Lancet JE, Cleveland JL, Padron E, List AF. Sallman DA, et al. Blood. 2020 Dec 10;136(24):2812-2823. doi: 10.1182/blood.2020006158. Blood. 2020. PMID: 32730593 Free PMC article.
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.
Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. Basiorka AA, et al. Among authors: sallman da. Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13. Blood. 2016. PMID: 27737891 Free PMC article.
Mutation-Driven Therapy in MDS.
Swoboda DM, Sallman DA. Swoboda DM, et al. Among authors: sallman da. Curr Hematol Malig Rep. 2019 Dec;14(6):550-560. doi: 10.1007/s11899-019-00554-4. Curr Hematol Malig Rep. 2019. PMID: 31760573 Review.
Targeting TP53 Mutations in Myelodysplastic Syndromes.
Hunter AM, Sallman DA. Hunter AM, et al. Among authors: sallman da. Hematol Oncol Clin North Am. 2020 Apr;34(2):421-440. doi: 10.1016/j.hoc.2019.11.004. Epub 2019 Dec 12. Hematol Oncol Clin North Am. 2020. PMID: 32089220 Review.
Novel therapies in myelodysplastic syndromes.
Swoboda DM, Gesiotto Q, Sallman DA. Swoboda DM, et al. Among authors: sallman da. Curr Opin Hematol. 2020 Mar;27(2):58-65. doi: 10.1097/MOH.0000000000000562. Curr Opin Hematol. 2020. PMID: 31972686 Review.
70 results